134 related articles for article (PubMed ID: 20074281)
1. Rilonacept--CAPS and beyond.
Stahl N; Radin A; Mellis S
Ann N Y Acad Sci; 2009 Dec; 1182():124-34. PubMed ID: 20074281
[TBL] [Abstract][Full Text] [Related]
2. Rilonacept in the treatment of chronic inflammatory disorders.
McDermott MF
Drugs Today (Barc); 2009 Jun; 45(6):423-30. PubMed ID: 19649332
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
4. Cryopyrin-associated periodic syndromes: background and therapeutics.
Kubota T; Koike R
Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
[TBL] [Abstract][Full Text] [Related]
5. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS).
Hoffman HM
Expert Opin Biol Ther; 2009 Apr; 9(4):519-31. PubMed ID: 19344287
[TBL] [Abstract][Full Text] [Related]
6. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
7. Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?
Koné-Paut I; Piram M
Autoimmun Rev; 2012 Nov; 12(1):77-80. PubMed ID: 22884551
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).
Radin A; Marbury T; Osgood G; Belomestnov P
J Clin Pharmacol; 2010 Jul; 50(7):835-41. PubMed ID: 20035038
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
11. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).
Gillespie J; Mathews R; McDermott MF
J Inflamm Res; 2010; 3():1-8. PubMed ID: 22096352
[TBL] [Abstract][Full Text] [Related]
12. Rilonacept and canakinumab.
Dubois EA; Rissmann R; Cohen AF
Br J Clin Pharmacol; 2011 May; 71(5):639-41. PubMed ID: 21375570
[No Abstract] [Full Text] [Related]
13. Treatment of autoinflammatory syndromes.
Gattorno M; Martini A
Curr Opin Pediatr; 2010 Dec; 22(6):771-8. PubMed ID: 20966753
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
Church LD; McDermott MF
Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
[TBL] [Abstract][Full Text] [Related]
16. The Future of IL-1 Targeting in Kidney Disease.
Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
[TBL] [Abstract][Full Text] [Related]
17. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
Church LD; Savic S; McDermott MF
Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
[TBL] [Abstract][Full Text] [Related]
18. Cryopyrin-associated periodic syndrome.
Posch C; Kaulfersch W; Rappersberger K
Pediatr Dermatol; 2014; 31(2):228-31. PubMed ID: 22891689
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study.
Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M
Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335
[TBL] [Abstract][Full Text] [Related]
20. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
